Concizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Concizumab
DrugBank Accession Number
DB12820
Background

Concizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Concizumab

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Concizumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Concizumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Concizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Concizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Concizumab.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AlhemoSolution60 mg / 1.5 mLSubcutaneousNovo NordiskNot applicableNot applicableCanada flag
AlhemoSolution300 mg / 3 mLSubcutaneousNovo NordiskNot applicableNot applicableCanada flag
AlhemoSolution15 mg / 1.5 mLSubcutaneousNovo NordiskNot applicableNot applicableCanada flag
AlhemoSolution150 mg / 1.5 mLSubcutaneousNovo NordiskNot applicableNot applicableCanada flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
68603V9EAF
CAS number
1312299-39-0

References

General References
Not Available
PubChem Substance
347911387

Clinical Trials

Clinical Trials

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionSubcutaneous15 mg / 1.5 mL
SolutionSubcutaneous150 mg / 1.5 mL
SolutionSubcutaneous300 mg / 3 mL
SolutionSubcutaneous60 mg / 1.5 mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 21, 2016 00:30 / Updated at February 21, 2021 18:54